2022 Ontario study shows Bavarian Nordic's MVA-BN smallpox vaccine has 58% effectiveness in preventing monkeypox after one dose.

A study in Ontario reveals that Bavarian Nordic's smallpox vaccine, MVA-BN, shows moderate effectiveness, estimated at 58%, in preventing monkeypox (mpox) infection after one dose. Conducted during the 2022 outbreak, the research highlights the vaccine's potential to aid in controlling the virus, particularly among high-risk groups. The findings suggest the need for rapid availability of the vaccine to support ongoing public health efforts against mpox.

September 11, 2024
83 Articles